therascreen FGFR RGQ RT-PCR Kit - For qualitative detection of actionable alterations in the FGFR3 gene.
therascreen FGFR RGQ RT-PCR Kit
For qualitative detection of actionable alterations in the FGFR3 gene
- FDA-approved FGFR alteration assay
- Detection of four point mutations and two fusions in the FGFR3 gene
- High sensitivity and specificity
- Simple workflow with next-day results
- Automated data analysis using Rotor-Gene AssayManager v2.1 software
The therascreen FGFR RGQ RT-PCR Kit is a qualitative in vitro diagnostic test for the detection of two point mutations in exon 7 [p.R248C (c.742C>T), p.S249C (c.746C>G)], two point mutations in exon 10 [p.G370C (c.1108G>T) and p.Y373C (c.1118A>G)] and two fusions (FGFR3:TACC3v1 and FGFR3:TACC3v3) in the FGFR3 gene.
The therascreen FGFR RGQ RT-PCR Kit is the only FDA-approved companion diagnostic (CDx) test for the identification of patients with cases of urothelial cancer (UC) that harbor these actionable FGFR alterations, and for whom treatment with BALVERSA (erdafitinib) is indicated.
Product Overview
